Tempus AI Launches Million Genome Initiative: A New Milestone in AI-Driven Precision Medicine

Initiative Overview

On September 11, 2026, Tempus AI (NASDAQ: TEM) officially announced the launch of an ambitious strategic initiative: building the world's first disease-centric, multimodal whole-genome sequencing (WGS) dataset linked to longitudinal clinical outcomes.

The near-term goal of this initiative is to compile 100,000 disease-specific whole genomes, with a long-term objective of expanding the repository to 1 million genomes. This represents not just a breakthrough in scale, but a fundamental transformation in the paradigm of AI-driven medical research.

Why Whole Genome Sequencing Matters

Traditional genomic research has primarily relied on whole exome sequencing (WES), which covers only about 1-2% of the genome's coding regions. Whole genome sequencing (WGS) covers the entire genome, including:

• Non-coding regions: Comprising more than 98% of the genome, containing numerous regulatory elements
• Structural variants: Large-scale insertions, deletions, inversions, and translocations
• Copy number variants (CNVs): Duplications or deletions of genomic segments
• Single nucleotide polymorphisms (SNPs): Affecting disease risk and drug response

For cancer research, WGS can identify driver mutations that WES cannot detect, providing a more complete molecular profile for precision treatment.

What Makes Tempus's Dataset Unique

Tempus AI's initiative stands out for its multimodal integration design:

Data Integration Dimensions

This multimodal integration enables researchers to answer key questions such as:

• How do specific genomic variants affect treatment response?
• Which genomic features predict better prognosis?
• How can treatment plans be personalized based on genomic characteristics?

"Model-Ready" Environment

Unlike traditional population-scale genomic programs, Tempus's platform is optimized for AI training from the ground up:

• Supports pre-training and post-training workflows: Researchers can build and validate AI models directly on the platform
• Accessible through the Tempus Lens system: No need to move datasets between disparate systems
• De-identified processing: All data undergoes rigorous privacy protection

Synergy with Tempus's Existing Platforms

Tempus AI's whole genome initiative does not exist in isolation but is deeply integrated with its existing platforms:

Tempus Next Platform

In May 2026, Tempus expanded the Next platform with six new clinical scenarios covering breast, colorectal, ovarian, prostate, and urothelial cancers. In a multi-center prospective study of early-stage non-small cell lung cancer (eNSCLC):

• ALK testing rates improved by +24% (absolute)
• EGFR testing rates improved by +18% (absolute)
• PD-L1 testing rates improved by +13% (absolute)
• 89% of treated patients received guideline-concordant therapy

Tempus Lens Platform

In June 2026, Tempus launched the next-generation version of its Lens platform, an agentic AI tool focused on drug development and clinical trial design. The whole genome dataset will provide richer training data for Lens.

Market Context: The AI Revolution in Precision Medicine

Tempus AI's initiative launches against the backdrop of rapidly advancing AI in precision medicine:

Competitive Landscape

• Illumina: The world's largest gene sequencing equipment manufacturer, developing AI analysis tools
• Foundation Medicine: Roche's oncology genomics company, focused on cancer genome analysis
• Guardant Health: Leader in liquid biopsy, using AI to analyze circulating tumor DNA
• Microsoft BioEmu: Microsoft's protein design AI tool, accelerating drug discovery

Tempus's differentiation lies in its deep integration of longitudinal clinical data — not just genomic data, but patients' complete diagnosis and treatment histories, a core advantage that competitors find difficult to replicate.

Investor Attention

Tempus AI has continued to attract investor attention in 2026, with its AI-driven precision medicine platform viewed as an important target in the healthcare AI sector. Analysts particularly focus on:

• The moat effect of its data assets
• Partnerships with major healthcare systems
• Expansion potential into drug development

Asia-Pacific Precision Medicine Opportunities

For the Asia-Pacific region, Tempus AI's whole genome initiative has special significance:

Genomic Diversity of Asia-Pacific Populations

Asia-Pacific populations account for approximately 60% of the global population but are severely underrepresented in existing genomic databases. Most genomic research is based on European-ancestry populations, leading to:

• Lower accuracy in disease risk prediction for Asian patients
• Lack of pharmacogenomics data for Asian populations
• Insufficient research on genetic variants more common in Asian populations

Asia-Pacific Collaboration Opportunities

Tempus's Early Adopter Program provides opportunities for Asia-Pacific healthcare institutions to participate. Leading medical centers in Japan, South Korea, Singapore, and other countries can gain access to the platform by contributing local patient data (under strict privacy protection frameworks).

Regulatory Environment

Countries across Asia-Pacific are actively establishing genomic data governance frameworks:

• Japan: The Next-Generation Medical Infrastructure Act provides a legal framework for secondary use of genomic data
• Singapore: The Personal Data Protection Act (PDPA) is being updated to address the unique nature of genomic data
• China: The Human Genetic Resources Administration Regulations impose strict restrictions on cross-border transfer of genomic data

Timeline and Availability

Conclusion: A New Era of Genomic AI

Tempus AI's million genome initiative represents an important milestone in AI-driven precision medicine. By deeply integrating whole genome sequencing data with longitudinal clinical outcomes and building a "model-ready" research environment, Tempus is laying the foundation for the next generation of AI-driven medical breakthroughs.

For healthcare institutions and researchers in the Asia-Pacific region, now is the optimal time to actively participate in this initiative — not only to gain access to cutting-edge research tools, but also to ensure that Asia-Pacific populations are not marginalized in the global precision medicine revolution.